# Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

> **NCT05163223** · PHASE2 · TERMINATED · sponsor: **Aston Sci. Inc.** · enrollment: 10 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** AST-301(pNGVL3-hICD)
- **DRUG:** rhuGM-CSF
- **DRUG:** Placebo
- **DRUG:** Pembrolizumab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT05163223
- **Lead sponsor:** Aston Sci. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-28
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Difficulty in recruiting patients
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05163223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05163223, "Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05163223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*